EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies

Federico Spataro iD, Antonio Giovanni Solimando iD, Attilio Di Girolamo, Angelo Vacca, Roberto Ria

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.14333 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Federico Spataro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Post Graduate School in Allergology and Internal Medicine "Guido Baccelli", Department of Precision and Regenerative Medicine and Ionian Area-(DiMePR…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Granulomatosis with Polyangiitis, Immunosuppressive Agents, Churg-Strauss Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: "Research initiatives for innovative technologies and pathways in the health and welfare sector" D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion ini….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Eosinophilic granulomatous polyangiitis (EGPA) is a rare autoimmune disease characterized by multisystemic inflammation, with eosinophils playing a central role in its pathogenesis. Traditional management relies heavily on corticosteroids and immunosuppressants, which are associated with significant side effects. The emergence of biologic agents, such as benralizumab, offers targeted therapeutic options by inhibiting the interleukin‐5 receptor α, thereby reducing eosinophilic inflammation.

Methods

This systematic review and meta‐analysis comprehensively evaluate the efficacy and safety of benralizumab in EGPA patients, focusing on its ability to reduce oral corticosteroid (OCS) use, facilitate remission and spare immunosuppressants. We searched MEDLINE, LILACS and ISI Web of Science databases for relevant studies up to July 2024.

Results

Eight studies, including both randomized controlled trials (RCTs) and observational studies, were included in the meta‐analysis, involving a total of 396 EGPA patients. The pooled analysis demonstrated a significant reduction in OCS dose, with an overall estimated effect of −8.25 mg/day (95% CI, −9.39 to −7.10). Complete remission was achieved in 56.8% of patients, and immunosuppressants were reduced or discontinued in 28.1% of cases. Adverse events (AEs) were reported in 21.9% of patients, with only one discontinuation due to an AE.

Conclusion

These findings provide robust evidence supporting the use of benralizumab as an effective and well‐tolerated treatment option for EGPA, significantly reducing OCS requirements and offering promising remission rates. Future research should focus on larger, multicentre RCTs to confirm these findings and further elucidate the long‐term benefits and safety profile of benralizumab in EGPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGranulomatosis with PolyangiitisImmunosuppressive AgentsChurg-Strauss SyndromeHumansRandomized Controlled Trials as TopicAdrenal Cortex HormonesRemission InductionObservational Studies as Topic

Stichwörter der Autor:innen

EGPAanti‐IL5rbenralizumabmeta‐analysis

Substanzen

benralizumabAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Post Graduate School in Allergology and Internal Medicine "Guido Baccelli", Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Bari, Italy.
  • Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Bari, Italy.

ORCID-Profile: Federico Spataro, Antonio Giovanni Solimando

Förderung

  • "Research initiatives for innovative technologies and pathways in the health and welfare sector" D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion ini…

Zitieren

APA

Spataro, F., Solimando, A. G., Di Girolamo, A., Vacca, A., & Ria, R. (2025). Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14333

Vancouver

Spataro F, Solimando AG, Di Girolamo A, Vacca A, Ria R. Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.14333

BibTeX
@article{Spataro2025,
  author = {Spataro, Federico and Solimando, Antonio Giovanni and Di Girolamo, Attilio and Vacca, Angelo and Ria, Roberto},
  title = {Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.14333}
}
Kostenlos starten →